A practical reference on thymic extract: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
While scientists were trying to create a new antidepressant to inhibit the NE re-uptake they accidentally synthesised two new compounds, named talopram and talsupram. The two compounds where not marketed in spite of being potent SNRIs because a number of suicide attempts were reported in clinical trials. With minor changes to the chemical structure of talopram (figure 6), including a single 6-cyano (CN) substitution, scientists were able to convert talopram into a potent SSRI, called citalopram. But citalopram can also be viewed as a constrained analogue of paroxetine.
=== Relaxing temperature requirements === The typical recommendation of storage 2–8 °C (36–46 °F), often worded as a "requirement" on the label, is mainly derived from the cold chain guideline of the Expanded Program on Immunization as a matter of tradition. Vaccines are not routinely tested for their stability at higher temperatures. In places with unreliable power supply, this leads to doses of vaccines that are potentially still effective being written off when the cold chain is interrupted, or no attempt to supply the vaccine to be even done due to the perceived cost of the cold chain. Similarly, many vaccines carry an unnecessary "do not freeze" instruction. Both WHO and PATH have published compilations on the stability of vaccines beyond the recommended temperature range, specifically for heat and freezing. Studies have found that when vaccines are allowed to go outside the cold chain (OCC), vaccination coverage are increased, sometimes by 2–3 fold. The WHO has since formalized this approach as controlled temperature chain (CTC), where vaccines able to withstand room temperatures (up to 40 °C (104 °F) for days) and used for campaigns or special delivery (not routine immunization) are considered for approval. MenAfriVac was licensed (prequalified) for CTC in 2012 and has seen great success in the African meningitis belt. As of 2021, the only other CTC-prequalified vaccine is Gardasil which is yet to see wide use. PCV13 was CTC approved until 2016 when it was removed to allow consistent labeling.
=== Planets === Though many other civilisations in the Culture books live on planets, the Culture as currently developed has little direct connection to on-planet existence. Banks has written that he presumes this to be an inherent consequence of space colonisation, and a foundation of the liberal nature of the Culture. A small number of home worlds of the founding member-species of the Culture receive a mention in passing, and a few hundred human-habitable worlds were colonised (some of them terraformed) before the Culture elected to turn towards artificial habitats, preferring to keep the planets it encounters wild. Since then, the Culture has come to look down on terraforming as inelegant, ecologically problematic and possibly even immoral. Less than one per cent of the population of the Culture lives on planets, and many find the very concept somewhat bizarre. This attitude is not absolute though; in Consider Phlebas, some Minds suggest testing a new technology on a "spare planet" (knowing that it could be destroyed in an antimatter explosion if unsuccessful). One could assume – from Minds' usual ethics – that such a planet would have been lifeless to start with. It is also quite possible, even probable, that the suggestion was not made in complete seriousness.
==== Medical waste management program ==== California created the Medical Waste Management Program, which regulates the generation, handling, storage, treatment, and disposal of medical waste by providing oversight for the implementation of the Medical Waste Management Act. Precautions have been taken in California which permits and inspects all medical waste offsite treatment facilities and medical waste transfer stations. In order to dispose waste, the department recommends the following process to make controlled substance waste non-retrievable. Pills containing a controlled substance are crushed before placing the residue into a pharmaceutical waste container. Controlled substance that is remaining in a syringe is wasted into a pharmaceutical waste container before disposing of the syringe in a sharps container. Expired medications should be returned through a reverse distributor.
Different functional groups have different pKa values and bond strengths (single, double, triple) leading to increased electrophilicity with lower pKa and increased nucleophile strength with higher pKa. More basic/nucleophilic functional groups desire to attack an electrophilic functional group with a lower pKa on another molecule (intermolecular) or within the same molecule (intramolecular). Any group with a net acidic pKa that gets within range, such as an acyl or carbonyl group is fair game. Since the likelihood of being attacked decreases with an increase in pKa, acyl chloride components with the lowest measured pKa values are most likely to be attacked, followed by carboxylic acids (pKa = 4), thiols (13), malonates (13), alcohols (17), aldehydes (20), nitriles (25), esters (25), then amines (35). Amines are very basic, and are great nucleophiles/attackers.
Sources: en.wikipedia.org
The chief characteristic of proteins that allows their diverse set of functions is their ability to bind other molecules specifically and tightly. The region of the protein responsible for binding another molecule is known as the binding site and is often a depression or "pocket" on the molecular surface. This binding ability is mediated by the tertiary structure of the protein, which defines the binding site pocket, and by the chemical properties of the surrounding amino acids' side chains. Protein binding can be extraordinarily tight and specific; for example, the ribonuclease inhibitor protein binds to human angiogenin with a sub-femtomolar dissociation constant (< 10−15 M) but does not bind at all to its amphibian homolog onconase (> 1 M). Extremely minor chemical changes such as the addition of a single methyl group to a binding partner can sometimes suffice to nearly eliminate binding; for example, the aminoacyl tRNA synthetase specific to the amino acid valine discriminates against the very similar side chain of the amino acid isoleucine. Proteins can bind to other proteins as well as to small-molecule substrates. When proteins bind specifically to other copies of the same molecule, they can oligomerize to form fibrils; this process occurs often in structural proteins that consist of globular monomers that self-associate to form rigid fibers.
Most animals rely on biomass and bioenergy produced by plants and phytoplanktons (collectively called producers) through photosynthesis. Herbivores, as primary consumers, eat the plant material directly to digest and absorb the nutrients, while carnivores and other animals on higher trophic levels indirectly acquire the nutrients by eating the herbivores or other animals that have eaten the herbivores. Animals oxidise carbohydrates, lipids, proteins and other biomolecules in cellular respiration, which allows the animal to grow and to sustain basal metabolism and fuel other biological processes such as locomotion. Of the 550 gigatons of carbon biomass on Earth, animals account for 2 gigatons. Some benthic animals living close to hydrothermal vents and cold seeps on the dark sea floor consume organic matter produced through chemosynthesis (via oxidising inorganic compounds such as hydrogen sulfide) by archaea and bacteria. Animals originated in the ocean; all extant animal phyla, except for Micrognathozoa and Onychophora, feature at least some marine species. However, several lineages of arthropods begun to colonise land around the same time as land plants, between 510 and 471 million years ago, during the Late Cambrian or Early Ordovician periods. Vertebrates such as the lobe-finned fish Tiktaalik started to move on to land in the late Devonian, about 375 million years ago.
== External links == Indium Archived 2023-03-13 at the Wayback Machine at The Periodic Table of Videos (University of Nottingham) Reducing Agents > Indium low valent Archived 2023-07-09 at the Wayback Machine NIOSH Pocket Guide to Chemical Hazards Archived 2015-12-08 at the Wayback Machine (Centers for Disease Control and Prevention) usgs.gov (Mineral Commodity Summaries 2025): Indium
The history of Calabria has one of the oldest records of human presence in Italy, beginning around 700,000 BCE when a type of Homo erectus left traces around coastal areas. During the Paleolithic period Stone Age humans created the "Bos Primigenius", a figure of a bull on a cliff created around 10,000 BCE in the Romito Cave in the town of Papasidero. When the Neolithic period came the first villages were founded, around 3,500 BCE. Calabria was at one time the center of the European silk industry.
== Relationship with Eucalyptus Health == Juniper is part of Eucalyptus Health's portfolio of healthcare brands, alongside Pilot, Kin, Software and Compound. By 2025, the United Kingdom had become Eucalyptus Health's largest market. During this time, there was a period of medication shortage (notably Ozempic) so Eucalyptus temporarily paused new Juniper memberships in the UK to prioritise supply for existing patients, resuming uptake once supply constraints eased. In March 2025, Eucalyptus generated approximately A$200 million in revenue over the preceding 18 months from weight-loss services and medications across its brands, with revenue rising 55 per cent year-on-year to A$120.9 million. This growth aligned with improved supply of GLP-1 medications alongside the company's expansion in several international markets. In May 2025, Eucalyptus entered early discussions for an A$100–150 million funding round, positioning the company for a valuation exceeding A$1 billion (unicorn status). Eucalyptus became one of Australia's largest online weight-loss medication providers and its growth attracted both investor interest and regulatory scrutiny.
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.